Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 1/20 | 0.34 |
| ▸ | IDO1 | P14902 | 1/20 | 0.32 |
| ▸ | CA12 | O43570 | 2/20 | 0.32 |
| ▸ | CA1 | P00915 | 2/20 | 0.32 |
| ▸ | CA2 | P00918 | 2/20 | 0.32 |
| ▸ | CA7 | P43166 | 2/20 | 0.32 |
| ▸ | CA9 | Q16790 | 2/20 | 0.32 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | PARP1 | P09874 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18043789 | 0.78 | MMP2 (0.50) | MMP2IDO1CA12CA1CA2 | |
| SCHEMBL1822947 | 0.77 | ALDH1A1 (0.52) | IDO1ALDH1A1L3MBTL1 | |
| SCHEMBL6165261 | 0.76 | ALDH1A1 (0.37) | IDO1ALDH1A1L3MBTL1PARP1 | |
| SCHEMBL31092004 | 0.74 | RAB9A (0.45) | CA12CA1CA2CA7CA9 | |
| SCHEMBL11471190 | 0.74 | RAB9A (0.45) | CA12CA1CA2CA7CA9 | |
| SCHEMBL3322710 | 0.74 | HDAC4 (0.38) | MMP2CA12CA1CA2CA7 | |
| SCHEMBL15412720 | 0.74 | ALDH1A1 (0.46) | ALDH1A1L3MBTL1 | |
| SCHEMBL29628297 | 0.73 | TSHR (0.46) | ALDH1A1L3MBTL1 | |
| SCHEMBL5685123 | 0.73 | KDM4C (0.35) | ALDH1A1L3MBTL1PARP1 | |
| SCHEMBL2197897 | 0.70 | ALDH1A1 (0.38) | IDO1ALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4017854-B1 | PYRAZINO[1,2-B]QUINAZOLINE-3,6-DIONES DERIVATIVES, THEIR PRODUCTION AND USES THEREOF | CIIMAR CENTRO INTERDISCIPLINAR DE INVESTIG MARINHA E AMBIENTAL (PT) | 2025-08-13 | — | — | EP | disclosed |
| US-20220274987-A1 | PYRAZINO [1,2-B]QUINAZOLINE-3,6-DIONES DERIVATIVES, THEIR PRODUCTION AND USES THEREOF | UNIVERSIDADE NOVA DE LISBOA (PT) | 2022-09-01 | — | — | US | disclosed |
| EP-4017854-A1 | PYRAZINO [1,2-B]QUINAZOLINE-3,6-DIONES DERIVATIVES, THEIR PRODUCTION AND USES THEREOF | CIIMAR - Centro Interdisciplinar de Investigação Marinha e Ambiental (PT) | 2022-06-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220274987-A1 | PYRAZINO [1,2-B]QUINAZOLINE-3,6-DIONES DERIVATIVES, THEIR PRODUCTION AND USES THEREOF | NQO2, G6PD, QDPR | MMP2 2273/4885IDO1 990/4885CA12 4851/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.